From vaccines to gene therapies, mRNA medicines often rely on tiny fat-based particles called lipid nanoparticles, or LNPs, to carry treatments where they need to go. But researchers still face a fundamental challenge: getting those therapies to the organs where they are needed most while limiting side effects elsewhere in the body.